6533b857fe1ef96bd12b3a46
RESEARCH PRODUCT
Validation of a plasma metabolomics model that allows anticipation of the occurrence of cytomegalovirus DNAaemia in allogeneic stem cell transplant recipients.
José Luis PiñanaDaniel MonleonAriadna PérezAlberto TalayaDavid NavarroJosé Manuel MoralesCarlos SolanoEstela GiménezJuan Carlos Hernández-boludaVíctor Vinuesasubject
0301 basic medicineMicrobiology (medical)Taurinebusiness.industryGeneral MedicineMicrobiologyTransplantation03 medical and health sciencesHaematopoiesischemistry.chemical_compound030104 developmental biologyMetabolomicschemistryBaseline characteristicsCohortImmunologyMedicineCholineStem cellbusinessdescription
A plasma metabolomic model obtained by means of untargeted 1H nuclear magnetic resonance, to which taurine, choline, methylamine, total glutathione, trimethylamine N-oxide, lactate, lysine, isoleucine, total fatty acids and unsaturated fatty acids contributed, was validated for the prediction of first episodes of cytomegalovirus (CMV) DNAaemia in a cohort of 79 allogeneic stem haematopoietic stem cell transplant (allo-HSCT) recipients. The predictive success rate was nearly 65 % for patients at both low and high risk of CMV-related complications according to their baseline characteristics. Plasma metabolomics profiling shortly after engraftment (day 21 after transplantation) allowed the anticipation of the occurrence of CMV DNAaemia in 71 % of patients. Plasma metabolomics analyses may be ancillary for identifying allo-HSCT patients at the highest risk of CMV DNAaemia who may benefit from early targeted antiviral prophylaxis.
year | journal | country | edition | language |
---|---|---|---|---|
2018-06-01 | Journal of medical microbiology |